FDA grants approval for Veklury use in Covid-19 patients
This therapy is intended for use in patients with severe renal impairment including those on dialysis. The latest announcement comes after the decision from European Commission to extend
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.